Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 11.00% and Operating profit at -25.90% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 9.15% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 11.00% and Operating profit at -25.90% over the last 5 years
3
The company has declared negative results for the last 6 consecutive quarters
4
With ROE of 2.57%, it has a very expensive valuation with a 9.92 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 19,155 Million (Large Cap)
386.00
NA
0.21%
0.72
1.27%
7.82
Revenue and Profits:
Net Sales:
325 Million
(Quarterly Results - Mar 2026)
Net Profit:
10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
43.87%
0%
43.87%
6 Months
25.22%
0%
25.22%
1 Year
29.78%
0%
29.78%
2 Years
93.55%
0%
93.55%
3 Years
207.38%
0%
207.38%
4 Years
215.38%
0%
215.38%
5 Years
79.33%
0%
79.33%
BrightGene Bio-Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.00%
EBIT Growth (5y)
-25.90%
EBIT to Interest (avg)
25.45
Debt to EBITDA (avg)
3.56
Net Debt to Equity (avg)
0.57
Sales to Capital Employed (avg)
0.26
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
21.42%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.70%
ROE (avg)
9.15%
Valuation key factors
Factor
Value
P/E Ratio
386
Industry P/E
Price to Book Value
9.92
EV to EBIT
310.42
EV to EBITDA
112.54
EV to Capital Employed
6.41
EV to Sales
22.71
PEG Ratio
NA
Dividend Yield
0.17%
ROCE (Latest)
2.07%
ROE (Latest)
2.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
324.90
349.40
-7.01%
Operating Profit (PBDIT) excl Other Income
8.70
26.90
-67.66%
Interest
18.60
14.60
27.40%
Exceptional Items
2.60
12.30
-78.86%
Consolidate Net Profit
9.50
5.60
69.64%
Operating Profit Margin (Excl OI)
26.80%
-43.80%
7.06%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -7.01% vs 3.74% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 69.64% vs -81.14% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,220.00
1,279.60
-4.66%
Operating Profit (PBDIT) excl Other Income
204.50
310.70
-34.18%
Interest
63.90
53.80
18.77%
Exceptional Items
10.70
-10.10
205.94%
Consolidate Net Profit
37.00
141.30
-73.81%
Operating Profit Margin (Excl OI)
30.20%
150.80%
-12.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -4.66% vs 8.63% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -73.81% vs -18.51% in Dec 2024
About BrightGene Bio-Medical Technology Co., Ltd. 
BrightGene Bio-Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






